# Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)

> **NCT04268472** · NA · COMPLETED · sponsor: **Geropharm** · enrollment: 44 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** GP30101
- **DRUG:** Prezista®
- **DRUG:** GP30101
- **DRUG:** Prezista®

## Key facts

- **NCT ID:** NCT04268472
- **Lead sponsor:** Geropharm
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-06
- **Primary completion:** 2019-09-06
- **Final completion:** 2019-09-06
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04268472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04268472, "Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04268472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*